Remarkably, ABT-737 can disrupt the BCL2-ARTD1 interaction and promotes ARTD1 and poly-ADP-ribosylation dependent necrotic cell death in primary ATM wild-type CLL cells [564]. Here, ATM is linked to B-cell chronic lymphocytic leukemia.